{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T08:21:20Z","timestamp":1783153280238,"version":"3.54.6"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007270","name":"University of Michigan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01GM144401"],"award-info":[{"award-number":["R01GM144401"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.dmd.2026.100307","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:00:48Z","timestamp":1777474848000},"page":"100307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating plasma carboxylesterase 1 as a protein biomarker for pharmacokinetics and metabolic dysfunction\u2013associated steatotic liver disease"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1888-5252","authenticated-orcid":false,"given":"Sun Min","family":"Jung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8143-7017","authenticated-orcid":false,"given":"Xinwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0340-2323","authenticated-orcid":false,"given":"Lucy","family":"Her","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2248-4419","authenticated-orcid":false,"given":"Hao-Jie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.dmd.2026.100307_bib1","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1124\/dmd.106.009381","article-title":"Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine","volume":"34","author":"Imai","year":"2006","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2026.100307_bib2","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1124\/dmd.119.089680","article-title":"Carboxylesterase 1 and precision pharmacotherapy: pharmacogenetics and nongenetic regulators","volume":"48","author":"Her","year":"2020","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmd.2026.100307_bib3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/17425255.2024.2348491","article-title":"Regulation of carboxylesterases and its impact on pharmacokinetics and pharmacodynamics: an up-to-date review","volume":"20","author":"Liu","year":"2024","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"12","key":"10.1016\/j.dmd.2026.100307_bib4","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1111\/bcp.14888","article-title":"Effect of CES1 genetic variation on enalapril steady-state pharmacokinetics and pharmacodynamics in healthy subjects","volume":"87","author":"Her","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"30","key":"10.1016\/j.dmd.2026.100307_bib5","doi-asserted-by":"crossref","first-page":"20498","DOI":"10.1016\/S0021-9258(18)54952-8","article-title":"The COOH terminus of several liver carboxylesterases targets these enzymes to the lumen of the endoplasmic reticulum","volume":"266","author":"Robbi","year":"1991","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.dmd.2026.100307_bib6","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/cpt.2486","article-title":"Plasma carboxylesterase 1 predicts methylphenidate exposure: A proof-of-concept study using plasma protein biomarker for hepatic drug metabolism","volume":"111","author":"Shi","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.dmd.2026.100307_bib7","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.dmd.2026.100307_bib8","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.dmd.2026.100307_bib9","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jhep.2020.03.036","article-title":"Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis","volume":"73","author":"Vali","year":"2020","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100307_bib10","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.dmd.2026.100307_bib11","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1053\/j.gastro.2004.08.052","article-title":"Serum markers detect the presence of liver fibrosis: a cohort study","volume":"127","author":"Rosenberg","year":"2004","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.dmd.2026.100307_bib12","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/hep.23050","article-title":"Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study","volume":"50","author":"Feldstein","year":"2009","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.dmd.2026.100307_bib13","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s13238-017-0437-z","article-title":"Carboxylesterases in lipid metabolism: from mouse to human","volume":"9","author":"Lian","year":"2018","journal-title":"Protein Cell"},{"issue":"5","key":"10.1016\/j.dmd.2026.100307_bib14","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/hep.26714","article-title":"Hepatic carboxylesterase 1 is essential for both normal and farnesoid X receptor-controlled lipid homeostasis","volume":"59","author":"Xu","year":"2014","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.dmd.2026.100307_bib15","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.bbalip.2009.07.006","article-title":"Es-x\/Ces1 prevents triacylglycerol accumulation in McArdle-RH7777 hepatocytes","volume":"1791","author":"Ko","year":"2009","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"10.1016\/j.dmd.2026.100307_bib16","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/HEP.0000000000000300","article-title":"Plasma proteomic signature of fatty liver disease: the Rotterdam Study","volume":"78","author":"Abozaid","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.dmd.2026.100307_bib17","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13052-024-01733-7","article-title":"Increased serum carboxylesterase-1 levels are associated with metabolic dysfunction associated steatotic liver disease and metabolic syndrome in children with obesity","volume":"50","author":"Wang","year":"2024","journal-title":"Ital J Pediatr"},{"issue":"2","key":"10.1016\/j.dmd.2026.100307_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172463","article-title":"Increased liver-specific proteins in circulating extracellular vesicles as potential biomarkers for drug- and alcohol-induced liver injury","volume":"12","author":"Cho","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.dmd.2026.100307_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FPC.0b013e32835aa8a2","article-title":"The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response","volume":"23","author":"Lewis","year":"2013","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"10.1016\/j.dmd.2026.100307_bib20","doi-asserted-by":"crossref","first-page":"7244","DOI":"10.1038\/s41598-017-07736-1","article-title":"Effect of carboxylesterase 1 S75N on clopidogrel therapy among acute coronary syndrome patients","volume":"7","author":"Xiao","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.dmd.2026.100307_bib21","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/bcpt.12916","article-title":"Effects of genetic variants on carboxylesterase 1 gene expression, and clopidogrel pharmacokinetics and antiplatelet effects","volume":"122","author":"Neuvonen","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100307_bib22","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/cpt.101","article-title":"Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans","volume":"97","author":"Tarkiainen","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.dmd.2026.100307_bib23","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/j.xphs.2022.04.019","article-title":"Physiologically-based pharmacokinetic modeling to predict methylphenidate exposure affected by interplay among carboxylesterase 1 pharmacogenetics, drug-drug interactions, and sex","volume":"111","author":"Xiao","year":"2022","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.dmd.2026.100307_bib24","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bcpt.12835","article-title":"The pharmacokinetics of enalapril in relation to CES1 genotype in healthy Danish volunteers","volume":"121","author":"Stage","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100307_bib25","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1111\/cts.12989","article-title":"Impact of carboxylesterase 1 genetic polymorphism on trandolapril activation in human liver and the pharmacokinetics and pharmacodynamics in healthy volunteers","volume":"14","author":"Wang","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"2","key":"10.1016\/j.dmd.2026.100307_bib26","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/phar.1194","article-title":"The role of human carboxylesterases in drug metabolism: have we overlooked their importance?","volume":"33","author":"Laizure","year":"2013","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.dmd.2026.100307_bib27","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.cbpa.2009.04.620","article-title":"Prodrugs: bridging pharmacodynamic\/pharmacokinetic gaps","volume":"13","author":"Testa","year":"2009","journal-title":"Curr Opin Chem Biol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100307_bib28","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1124\/pr.110.003459","article-title":"Prodrugs-from serendipity to rational design","volume":"63","author":"Huttunen","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.dmd.2026.100307_bib29","article-title":"Carboxylesterase 1 is regulated by hepatocyte nuclear factor 4\u03b1 and Protects against alcohol- and MCD diet-induced liver injury","volume":"6","author":"Xu","year":"2016","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.dmd.2026.100307_bib30","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/hep.25961","article-title":"Deficiency of carboxylesterase 1\/esterase-x results in obesity, hepatic steatosis, and hyperlipidemia","volume":"56","author":"Quiroga","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.dmd.2026.100307_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115250","article-title":"Emerging role of carboxylesterases in nonalcoholic fatty liver disease","volume":"205","author":"Liu","year":"2022","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"10.1016\/j.dmd.2026.100307_bib32","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1124\/dmd.109.028209","article-title":"Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver","volume":"37","author":"Zhu","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2026.100307_bib33","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1124\/dmd.115.068957","article-title":"Age-dependent human hepatic carboxylesterase 1 (CES1) and carboxylesterase 2 (CES2) postnatal ontogeny","volume":"44","author":"Hines","year":"2016","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T08:06:31Z","timestamp":1783152391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626000760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0090955626000760"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100307","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating plasma carboxylesterase 1 as a protein biomarker for pharmacokinetics and metabolic dysfunction\u2013associated steatotic liver disease","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100307","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100307"}}